NCT06478043View on ClinicalTrials.gov

A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2027

Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
DRUG

ivonescimab

20mg/kg, IV, D1, Q3W

DRUG

irinotecan liposome

56.5mg/m\^2, IV, D1, Q2W

Trial Locations (1)

310022

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER